Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.

Ahn HK, Kim SJ, Hwang DW, Ko YH, Tang T, Lim ST, Kim WS.

Invest New Drugs. 2013 Apr;31(2):469-72. doi: 10.1007/s10637-012-9889-4. Epub 2012 Oct 28.

PMID:
23108598
2.

Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.

Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, Wang X, Ma W, Fu X, Wu J, Sun Z, Zhang X, Li Z, Yan J, Chang Y, Lu L, Qin B, Li X, Wen J, Zhang M.

Ann Hematol. 2014 Nov;93(11):1889-94. doi: 10.1007/s00277-014-2136-7. Epub 2014 Jun 13.

PMID:
24923454
3.

Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.

Guo Y, Lu JJ, Ma X, Wang B, Hong X, Li X, Li J.

Oral Oncol. 2008 Jan;44(1):23-30. Epub 2007 Feb 15.

PMID:
17306611
4.

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.

J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.

PMID:
21990393
5.

Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.

Wen JY, Li M, Li X, Chen J, Lin Q, Ma XK, Dong M, Wei L, Chen ZH, Wu XY.

Asian Pac J Cancer Prev. 2014;15(15):6275-81.

6.

Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Yang L, Liu H, Xu XH, Wang XF, Huang HM, Shi WY, Jiang SH.

Med Oncol. 2013 Dec;30(4):720. doi: 10.1007/s12032-013-0720-7. Epub 2013 Sep 24.

PMID:
24062259
7.

Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.

Offidani M, Mele A, Corvatta L, Marconi M, Malerba L, Olivieri A, Rupoli S, Alesiani F, Leoni P.

Leuk Lymphoma. 2002 Jun;43(6):1273-9.

PMID:
12152996
8.

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup.

Blood. 2011 Feb 10;117(6):1834-9. doi: 10.1182/blood-2010-09-307454. Epub 2010 Dec 1.

9.
10.

Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.

Zhong DT, Shi CM, Chen Q, Huang JZ, Liang JG.

Ann Hematol. 2012 Nov;91(11):1757-63. doi: 10.1007/s00277-012-1518-y. Epub 2012 Jul 13.

PMID:
22790106
11.

Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.

Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J.

Hematol Oncol. 2006 Mar;24(1):28-32.

PMID:
16323259
12.

Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.

Jing XM, Zhang ZH, Wu P, Zhang SC, Ren YR, Xiong ZJ, Wei W, Luo L, Li L.

Leuk Res. 2016 Aug;47:26-31. doi: 10.1016/j.leukres.2016.05.004. Epub 2016 May 12.

PMID:
27239738
13.

L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.

Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J.

Ann Hematol. 2009 Jul;88(7):647-52. doi: 10.1007/s00277-008-0669-3. Epub 2008 Dec 24.

PMID:
19107482
14.

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.

Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS.

Blood. 2012 Oct 11;120(15):2973-80. doi: 10.1182/blood-2012-05-431460. Epub 2012 Aug 23.

15.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
16.

Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type.

Yokoyama H, Yamamoto J, Tohmiya Y, Yamada MF, Ohguchi H, Ohnishi Y, Okitsu Y, Fukuhara N, Ohba-Ohtsuka R, Kohata K, Ishizawa K, Kameoka J, Harigae H.

Leuk Lymphoma. 2010 Aug;51(8):1509-12. doi: 10.3109/10428194.2010.487958.

PMID:
20496989
17.

First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.

Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ.

Cancer. 2013 Jan 15;119(2):348-55. doi: 10.1002/cncr.27752. Epub 2012 Jul 18.

18.

[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].

Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.

Ai Zheng. 2005 Apr;24(4):465-9. Chinese.

PMID:
15820071
19.

Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.

Li L, Zhang C, Zhang L, Li X, Wu JJ, Sun ZC, Fu XR, Wang XH, Chang Y, Wang R, Qiu YJ, Zhang MZ.

Neoplasma. 2014;61(2):225-32. doi: 10.4149/neo_2014_029.

PMID:
24299319
20.

Supplemental Content

Support Center